Brief: Isofol Medical Updates On ISO-CC-005 Phase I/IIA Study

Isofol Medical AB (publ)

30/09/2020 07:53

Sept 30 (Reuters) - Isofol Medical AB (publ)  ISOFOL.ST :
    * 55 % OVERALL RESPONSE RATE ON THE SAFETY EXTENSION COHORTS
OF
THE ISO-CC-005 PHASE I/IIA STUDY
    * DATA FOLLOWING 16-WEEKS OF TREATMENT AND BEYOND SHOWS BEST
OVERALL RESPONSE RATE (ORR) OF 55% IN 31 PATIENTS

Source text for Eikon:  ID:nWkr9xlK2x 
Further company coverage:  ISOFOL.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))